MGIM
NTLA icon

M&G Investment Management’s Intellia Therapeutics NTLA Stock Holding History

M&G Investment Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-19,169
Closed -$2.57K – 658
2021
Q3 		$2.57K Sell
19,169
-6,266
-25% -$949K 0.01% 485
2021
Q2 		$4.12K Buy
+25,435
New +$1.98M 0.01% 427

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

M&G Investment Management's NTLA Position: Q4 2021 in Review

M&G Investment Management sold out of Intellia Therapeutics (NTLA) in Q4 2021, closing a stake of 19,169 shares — an estimated $2.57K sold.

M&G Investment Management first reported a position in NTLA in Q2 2021 and held it in 2 quarters. The position peaked at $4.12K in Q2 2021. 371 funds tracked by Wall St. Rank hold NTLA as of Q4 2021.

  • M&G Investment Management reported no remaining Intellia Therapeutics position as of Q4 2021 after selling out during the quarter.
  • M&G Investment Management sold 19,169 Intellia Therapeutics shares in Q4 2021, an estimated $2.57K.
  • M&G Investment Management first reported a position in Intellia Therapeutics in Q2 2021 and held it in 2 quarters.
  • M&G Investment Management's Intellia Therapeutics position peaked at $4.12K in Q2 2021.
  • 371 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2021.

Based on M&G Investment Management's 13F filing for Q4 2021, filed 18 Jan 2022.